DURECT (NASDAQ:DRRX – Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $6.91 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
DURECT Trading Up 6.1 %
Shares of DRRX opened at $0.85 on Monday. The company has a market cap of $26.35 million, a price-to-earnings ratio of -1.39 and a beta of 0.91. The company’s fifty day simple moving average is $0.80 and its 200 day simple moving average is $1.02. DURECT has a 1-year low of $0.70 and a 1-year high of $1.88.
Analyst Upgrades and Downgrades
Separately, StockNews.com began coverage on shares of DURECT in a research note on Wednesday, March 19th. They issued a “sell” rating for the company.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Read More
- Five stocks we like better than DURECT
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 ETFs to Ride the VIX Surge During Market Volatility
- What Are Dividend Achievers? An Introduction
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
